Tesamorelin vs sermorelin: two GHRH analogs, very different status

Tesamorelin and sermorelin are constantly cross-shopped in the peptide world, usually under a vague “growth-hormone secretagogue” banner. The pairing is fair in one narrow sense and misleading in every other. Both are GHRH analogs — synthetic versions of growth-hormone-releasing hormone that prompt your own pituitary to release growth hormone, rather than injecting GH itself. But their regulatory status, evidence base, and actual approved purpose diverge sharply, and that is what most comparisons get wrong.

The one thing they share: mechanism

Native GHRH is a 44-amino-acid peptide. Both of these drugs are engineered fragments or stabilized versions of it that bind the GHRH receptor and stimulate pulsatile, endogenous GH secretion. Because the signal still runs through the pituitary's own feedback loops, GHRH analogs are often described as a more “physiologic” way to raise GH than recombinant growth hormone — but that framing is about mechanism, not about proven long-term benefit.

Tesamorelin: the one with current FDA approval and outcome data

Tesamorelin (brand name Egrifta) is a stabilized analog of GHRH(1–44) with a longer half-life than native GHRH. It is FDA-approved for one specific indication: reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. That approval rests on real randomized evidence. In the pivotal program, daily tesamorelin produced a significant reduction in visceral adipose tissue versus placebo, with the effect tied to its rise in IGF-1.^[1] So when someone reaches for tesamorelin, the honest description is: a GHRH analog with a defined, approved, trial-backed visceral-fat indication.

Sermorelin: historically approved, now mostly compounded

Sermorelin is a shorter analog — GHRH(1–29), the truncated active fragment of native GHRH. It also has a real regulatory history: as Geref, it was approved and used both to diagnose growth-hormone deficiency and to treat growth failure in children. A review of its clinical use documents that pedigree in idiopathic GH deficiency,^[2] and a multicenter study showed once-daily subcutaneous sermorelin accelerated growth in GH-deficient children during the first year of therapy.^[3] The key point for shoppers: the branded product was later discontinued commercially — a market decision, not a withdrawal for safety. Today sermorelin reaches patients almost entirely through compounding pharmacies, which means no FDA-approved finished product and the usual compounding caveats about standardization.

How they actually differ

Beyond the labels, the practical contrasts are: length and durability — tesamorelin is the longer, stabilized GHRH(1–44) analog, while sermorelin is the shorter GHRH(1–29) fragment with a briefer action; regulatory status — tesamorelin has a current FDA approval and a finished branded product, while sermorelin is now a compounded preparation; evidence — tesamorelin carries pivotal visceral-fat outcome data in a defined population, whereas sermorelin's strongest evidence is older and centered on pediatric GH-deficiency growth and diagnosis; and cost/access — compounded sermorelin is typically the cheaper, more accessible option, while tesamorelin is the pricier, on-label one. You can sit these side by side in the peptide evidence matrix.

What neither one is

Neither tesamorelin nor sermorelin is an evidence-backed general anti-aging therapy. Raising GH and IGF-1 is not the same as demonstrating that healthy adults live longer, look younger, or recover faster — and the trial data for both peptides sit in narrow, specific clinical contexts (HIV-associated visceral fat for one; pediatric GH deficiency for the other), not in healthy-aging populations. Marketing that blurs “raises GH” into “reverses aging” is running well ahead of the evidence for both.

A fair verdict framework

Match the drug to the question, not to the hype. If the goal is the one outcome with current approval and randomized support — reducing excess visceral fat in HIV-associated lipodystrophy — tesamorelin is the peptide with a finished, on-label product and pivotal data behind it. If someone is being offered sermorelin, the honest description is a historically approved, shorter-acting, now-compounded GHRH analog whose best evidence lives in pediatric GH deficiency, often chosen for lower cost and easier access rather than for any proven advantage in adults. Read the deeper monographs on tesamorelin (Egrifta) and sermorelin before deciding, and treat any “anti-aging” pitch for either as unproven.